Evaluation of Liposomal Bupivacaine Compared to Usual Care and Its Effects on Pain for Cardiac Surgery

• Status: Enrolling by invitation
• Trial end date: 2020-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of Liposomal Bupivacaine Compared to Usual Care and its Effect on Pain for Cardiac Surgery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Florida Heart and Lung Institute
• Collaborator: North Florida Regional Medical Center
• Treatments: Bupivacaine; Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Age >18 years old

• All open heart surgeries from September 1, 2019 - September 30, 2020

• Able to read, comprehend and sign the informed consent form

Exclusion Criteria:

• Pregnancy

• < 18 years old and prisoners

• Not able to sign informed consent, including patients with an (LAR) legally authorized representative

• Patients with chronic pain requiring scheduled narcotic use

• Stage 4 kidney disease, Child Pugh score suggestive of liver cirrhosis/ disease

• Recent MI within 7 days of scheduled Cardiac surgery

• Known allergy to Liposomal Bupivacaine or derivative of

• Have or is currently involved in a Research Study within 30 days of scheduled surgery